Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Ciska Buijs"'
Autor:
Hella E.C. Muijsers, Pensee Wu, Olivier W.H. van der Heijden, Lia D.E. Wijnberger, Chantal van Bijsterveldt, Ciska Buijs, Jens Pagels, Peter Tönnies, Susanne Heiden, Nel Roeleveld, Angela H.E.M. Maas
Publikováno v:
American Journal of Preventive Cardiology, Vol 12, Iss , Pp 100429- (2022)
Objectives: The risk of cardiovascular disease more than doubles after hypertensive disorders of pregnancy. As early onset chronic hypertension contributes to cardiovascular risk, implementation of screening strategies, using home blood pressure moni
Externí odkaz:
https://doaj.org/article/a68e56a05f6448b8ba3e0b9c4f2e1e74
Autor:
Hella E. C. Muijsers, Olivier W. H. van der Heijden, Karin de Boer, Chantal van Bijsterveldt, Ciska Buijs, Jens Pagels, Peter Tönnies, Susanne Heiden, Nel Roeleveld, Angela H. E. M. Maas
Publikováno v:
BMC Women's Health, Vol 20, Iss 1, Pp 1-6 (2020)
Abstract Background Hypertensive disorders of pregnancy (HDP), such as preeclampsia (PE) or the Hemolysis Elevated Liver enzymes and Low Platelets (HELLP) syndrome are associated with elevated cardiovascular disease (CVD) risks, but standardized prev
Externí odkaz:
https://doaj.org/article/d650101a9035463db27f6a0198a35de1
Autor:
Karin de Boer, Jens Pagels, Ciska Buijs, Hella E C Muijsers, Angela H.E.M. Maas, Chantal van Bijsterveldt, Susanne Heiden, Peter Tonnies, Nel Roeleveld, Olivier W.H. van der Heijden
Publikováno v:
BMC Women's Health, Vol 20, Iss 1, Pp 1-6 (2020)
BMC Women's Health, 20, 1
BMC Women's Health, 20
BMC Women's Health
BMC Women's Health, 20, 1
BMC Women's Health, 20
BMC Women's Health
Background Hypertensive disorders of pregnancy (HDP), such as preeclampsia (PE) or the Hemolysis Elevated Liver enzymes and Low Platelets (HELLP) syndrome are associated with elevated cardiovascular disease (CVD) risks, but standardized prevention gu
Publikováno v:
Statistics in Medicine. 28:3829-3843
SUMMARY This paper considers the analysis of longitudinal data complicated by the fact that during follow-up patients can be in different disease states, such as remission, relapse or death. If both the response of interest (for example, quality of l
Autor:
J. Marina Maurer, Peter Nieboer, C. H. Mom, Elisabeth G.E. de Vries, A. N.Mac Hteld Wymenga, H. Marike Boezen, Robert S. De Jong, Pax H.B. Willemse, Marian J.E. Mourits, Ciska Buijs
Publikováno v:
Breast Cancer Research and Treatment, 115(3), 573-580. Springer New York
Buijs, C, Mom, C H, Willemse, P H B, Marike Boezen, H, Maurer, J M, Wymenga, A N M H, De Jong, R S, Nieboer, P, De Vries, E G E & Mourits, M J E 2009, ' Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients : A double-blind, randomized cross-over study ', Breast Cancer Research and Treatment, vol. 115, no. 3, pp. 573-580 . https://doi.org/10.1007/s10549-008-0138-7
Breast Cancer Research and Treatment, 115(3), 573-580. SPRINGER
Buijs, C, Mom, C H, Willemse, P H B, Marike Boezen, H, Maurer, J M, Wymenga, A N M H, De Jong, R S, Nieboer, P, De Vries, E G E & Mourits, M J E 2009, ' Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients : A double-blind, randomized cross-over study ', Breast Cancer Research and Treatment, vol. 115, no. 3, pp. 573-580 . https://doi.org/10.1007/s10549-008-0138-7
Breast Cancer Research and Treatment, 115(3), 573-580. SPRINGER
Purpose Breast cancer patients with treatment-induced menopause experience frequent and severe hot flashes (HF). We compared venlafaxine and clonidine for the treatment of HF with regard to side effects, efficacy, quality of life and sexual functioni
Publikováno v:
CANCER TREATMENT REVIEWS. 34(7):640-655
Many hormonal modalities are available for breast cancer treatment, such as selective oestrogen receptor modulators (SERMs), aromatase inhibitors, progestins and luteinising hormone-releasing hormone (LHRH) agonists. The Long-term impact of these end
Autor:
Ciska Buijs, Louk V.A.M. Beex, Elisabeth G.E. de Vries, Peter Nieboer, Sjoerd Rodenhuis, Pierre Hupperets, Elsken van der Wall, Harm van Tinteren, Els M. TenVergert, Dick J. Richel, Caroline Seynaeve, Emile E. Voest, Nanno Mulder, Winette T. A. van der Graaf, Marianne A. Nooij
Publikováno v:
Journal of Clinical Oncology, 23, 33, pp. 8296-304
Journal of clinical oncology, 23(33), 8296. American Society of Clinical Oncology
Journal of Clinical Oncology, 23(33), 8296-8304. American Society of Clinical Oncology
Journal of clinical oncology, 23(33), 8296-8304. American Society of Clinical Oncology
Journal of Clinical Oncology, 23, 8296-304
Journal of Clinical Oncology, 23(33), 8296-8304. AMER SOC CLINICAL ONCOLOGY
Journal of clinical oncology, 23(33), 8296. American Society of Clinical Oncology
Journal of Clinical Oncology, 23(33), 8296-8304. American Society of Clinical Oncology
Journal of clinical oncology, 23(33), 8296-8304. American Society of Clinical Oncology
Journal of Clinical Oncology, 23, 8296-304
Journal of Clinical Oncology, 23(33), 8296-8304. AMER SOC CLINICAL ONCOLOGY
Purpose Determine whether standard or high-dose chemotherapy leads to changes in fatigue, hemoglobin (Hb), mental health, muscle and joint pain, and menopausal status from pre- to post-treatment and to evaluate whether fatigue is associated with thes
Autor:
Marian J.E. Mourits, Ciska Buijs
Publikováno v:
Annals of Oncology, 23(11), 2990-2990. Oxford University Press
Publikováno v:
Quality of Life Research, 19(1), 137-148. SPRINGER
Quality of Life Research, 19(1), 137-148. Springer, Cham
Quality of Life Research, 19(1), 137-148
Quality of Life Research
Quality of Life Research, 19(1), 137-148. Springer, Cham
Quality of Life Research, 19(1), 137-148
Quality of Life Research
Purpose The analysis of longitudinal health-related quality of life measures (HRQOL) can be seriously hampered due to informative drop-out. Random effects models assume Missing At Random and do not take into account informative drop-out. We therefore
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6511d5fe704684639d3b1a36ecc3e032
https://research.rug.nl/en/publications/1a8d7ffe-af5d-4661-ac44-5cd895e3d5a2
https://research.rug.nl/en/publications/1a8d7ffe-af5d-4661-ac44-5cd895e3d5a2
Autor:
Hendrika Boezen, E.G.E. de Vries, Harry Hollema, Klase A. Ten Hoor, Ciska Buijs, Pax H.B. Willemse, Marian J.E. Mourits
Publikováno v:
International Journal of Gynecological Cancer, 19(4), 677-681. LIPPINCOTT WILLIAMS & WILKINS
OBJECTIVE: Tamoxifen, a nonsteroidal antiestrogen, is the agent of choice in the treatment of premenopausal receptor-positive breast cancer. This study aimed to investigate the influence of tamoxifen on the menstrual cycle and serum hormone levels an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ce2cbe1d26cf0b86a93fd758a62ec65
https://research.rug.nl/en/publications/fe029b34-ff27-44bf-a158-b598a7d53774
https://research.rug.nl/en/publications/fe029b34-ff27-44bf-a158-b598a7d53774